OC.08.1: RANDOMISED MULTICENTRE PILOT DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF EVALUATING THE EFFICACY AND SAFETY OF MESALAZINE IN THE PREVENTION OF RECURRENCE OF DIVERTICULITIS: INTERIM ANALYSIS AFTER 24-MONTH FOLLOW-UP

Digestive and Liver Disease ◽

10.1016/s1590-8658(11)60193-x ◽

2011 ◽

Vol 43 ◽

pp. S135 ◽

Cited By ~ 1

Author(s):

F. Parente ◽

S. Bargiggia ◽

A. Prada ◽

A. Bortoli ◽

A. Giacosa ◽

...

Keyword(s):

Interim Analysis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Prevention Of Recurrence

Mo1540 THE EFFICACY AND SAFETY OF GCWB104 (FLOS LONICERA EXTRACT) IN FUNCTIONAL DYSPEPSIA: A SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Gastroenterology ◽

10.1016/s0016-5085(20)32906-1 ◽

2020 ◽

Vol 158 (6) ◽

pp. S-887-S-888

Author(s):

Nayoung Kim ◽

Yonghoon Choi ◽

Dong Ho Lee

Keyword(s):

Functional Dyspepsia ◽

Controlled Study ◽

Efficacy And Safety ◽

Single Center ◽

Double Blind ◽

Double Blind Placebo

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of AS-013, a Prostaglandin E1Prodrug, in Patients With Intermittent Claudication

Circulation ◽

10.1161/01.cir.95.9.2298 ◽

1997 ◽

Vol 95 (9) ◽

pp. 2298-2302 ◽

Cited By ~ 59

Author(s):

J.J.F. Belch ◽

P.R.F. Bell ◽

D. Creissen ◽

J.A. Dormandy ◽

R.C. Kester ◽

...

Keyword(s):

Intermittent Claudication ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Statement of Retraction: Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study

International Journal of Psychiatry in Clinical Practice ◽

10.1080/13651501.2021.1950437 ◽

2021 ◽

pp. 1-1

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study

British Journal of Dermatology ◽

10.1111/bjd.20690 ◽

2021 ◽

Author(s):

Y. Zhao ◽

L. Wu ◽

Q. Lu ◽

X. Gao ◽

X. Zhu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Chinese Patients ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Association between elcatonin use and cancer risk in Japan: A follow-up study after a randomized, double-blind, placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis

Osteoporosis and Sarcopenia ◽

10.1016/j.afos.2020.02.001 ◽

2020 ◽

Vol 6 (1) ◽

pp. 15-19

Author(s):

Hiroaki Okamoto ◽

Nayumi Shibazaki ◽

Takeshi Yoshimura ◽

Toyonobu Uzawa ◽

Toshitsugu Sugimoto

Keyword(s):

Cancer Risk ◽

Postmenopausal Osteoporosis ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Follow Up Study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis

Arthritis & Rheumatology ◽

10.1002/art.39722 ◽

2016 ◽

Vol 68 (9) ◽

pp. 2174-2183 ◽

Cited By ~ 55

Author(s):

Brad H. Rovin ◽

Ronald F. van Vollenhoven ◽

Cynthia Aranow ◽

Carrie Wagner ◽

Robert Gordon ◽

...

Keyword(s):

Lupus Nephritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Active Lupus Nephritis ◽

Active Lupus

Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2010.04508.x ◽

2010 ◽

Vol 33 (2) ◽

pp. 213-224 ◽

Cited By ~ 22

Author(s):

Y. Kinoshita ◽

K. Ashida ◽

M. Hongo ◽

Keyword(s):

Clinical Trial ◽

Reflux Disease ◽

Randomised Clinical Trial ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo

Double-blind, placebo-controlled study of the efficacy and safety of isotretinoin cream (0.05% w/w and 0.10% w/w) with sunscreens in the treatment of mild to moderate acne vulgaris

Journal of Dermatological Treatment ◽

10.1080/095466300300165183 ◽

2000 ◽

Vol 11 (1) ◽

pp. 7-14 ◽

Cited By ~ 3

Author(s):

A Langner ◽

W Stapor ◽

AE Donald ◽

GC Boorman

Keyword(s):

Acne Vulgaris ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

P.2.f.027 The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomised, double-blind, placebo-controlled study

European Neuropsychopharmacology ◽

10.1016/s0924-977x(14)70748-5 ◽

2014 ◽

Vol 24 ◽

pp. S468 ◽

Cited By ~ 12

Author(s):

J.A. Quiroz ◽

P. Tamburri ◽

D. Deptula ◽

L. Banken ◽

U. Beyer ◽

...

Keyword(s):

Major Depression ◽

Adjunctive Therapy ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo